LONDON, February 7 /PRNewswire/ --

NeuStar, Inc. (NYSE: NSR) today announced that Vodafone has selected NeuStar as its principal partner in the rollout of mobile Instant Messaging solutions to Vodafone customers.

Vodafone has deployed NeuStar's mobile IM solutions including its Mobile Messaging Gateway and NeuStar Clients to roll out Microsoft Windows Live Messenger to customers in Portugal, Italy, Spain, Netherlands, France (via SFR), Germany and the UK. Additionally, NeuStar has also supported the launch of Yahoo! Messenger in Portugal.

About NeuStar, Inc. and NeuStar Next Generation Messaging

STOCKHOLM, February 7 /PRNewswire/ -- During the annual GSMA Mobile World Congress in Barcelona the patented, interactive TV device ippi is presented in the Swedish pavilion. Using mobile networks, the award winning product has the ability to convert two billion TVs worldwide into communication centres for videos, photos, voice messages and email.

The ippi has gained much interest among mobile operators all over the world. It has also been nominated for the European ICT Prize and in the prestigious Global Mobile Awards for the most innovative technology development. In October 2007 it also won the influential Swedish Embedded Price.

Transform TVs Into Communication Centres

Mount Sinai researchers have discovered that the release of blood stem cells from bone marrow is regulated by the brain through the cyclical human biological clock, via adrenergic signals transmitted by the sympathetic nervous system. These new findings, published online today on the website of the journal Nature, point out that the harvest of stem cells for transplantation may be improved by timing it at the peak of their release.

The study describes the mechanisms at the molecular levels in which signals from the biological clock in the brain are sent via the sympathetic—or "fight or flight" branch—of the nervous system, directly to bone marrow stem cell niches. Researchers, using mice as a model, were able to show the rhythmic release and peak of stem cells in circulation during the mouse’s resting period, and that changes in the light cycle or an experimental “jet lag” altered the release patterns. This is the first time a study has demonstrated that the brain regulates a stem cell niche.

LONDON, February 7 /PRNewswire/ -- Misys (FTSE: MSY.L), the global application software and services company, today announces that the OJSC Bank VTB, the second largest bank in Russia with the biggest share of trade finance business in Financing Russian Exports/Imports in 2006 under EBRD Trade Facilitation Program, has successfully gone live with its award-winning trade finance system, Misys Trade Innovation. As a result of this, the bank is expecting to see an increased performance in its trade finance operations and thus deliver more results to its customers.

STOCKHOLM, Sweden, February 7 /PRNewswire/ --

- General availability of first announced software-based multi-party HD-video conferencing solution; enables delivery of affordable HD-video conferencing

Global IP Solutions (GIPS), the leading provider of media processing solutions, today announced the general availability of its High-Definition (HD) enabled video conferencing engines for service providers, developers, manufacturers and enterprises.

GIPS' new offering enables organizations to deliver software-based multi-party HD video conferencing. The software-based approach significantly reduces the cost of High Definition video conferencing, making it ideal for consumers or desk-top use in business.

PLEASANTON, California, February 7 /PRNewswire/ --

- The first ever on-demand, hands-on training program for the server virtualization industry is launched by Citrix to train its worldwide channel partners.

Toolwire, a leading innovator of experiential distance learning solutions announces their agreement with Citrix Systems, Inc. to develop and deliver an on-demand lab environment to train Citrix worldwide channel partners.

TOKYO, February 7 /PRNewswire/ --

ACCESS CO., LTD., a global provider of advanced software technologies to the mobile and beyond-PC markets, today announced that worldwide deployments of its NetFront(TM) products, notably NetFront(TM) Browser for mobile handsets and information appliances, surpassed 500 million at the end of January, 2008.

Researchers at the University of Arkansas for Medical Sciences (UAMS) have reported a 10-fold life extension in the complex animal C. elegans, tiny worms that live in the soil.

Reported in the February 2008 issue of the journal Aging Cell, the discovery was made by a team of researchers headed by Robert Shmookler Reis, professor in the UAMS Departments of Geriatrics, Biochemistry/Molecular Biology and Pharmacology/Toxicology and research scientist at the Central Arkansas Veterans Healthcare System.

Continued from Part 6: I interviewed Gary Taubes by phone a few weeks ago, shortly after he gave a talk about the main ideas of his new book — Good Calories, Bad Calories — at UC Berkeley. The interview lasted about 2 hours. This is part 7. SETH ROBERTS: I was a member of the Center for Weight and Health. But the other members didn’t know what I was up to, and had no idea it could have anything to do with actual weight loss.

GARY TAUBES: That’s one of the things I’ve found most amusing about obesity research, that you have this disconnect from pre-World War Two, when the people doing it were clinicians who were treating obese patients, to post-World War Two, where first, it’s nutritionists, who do rat experiments. Then, by the 1960s, obesity is considered an eating disorder and it’s being treated by psychologists and psychiatrists. So today, if you looking at some of the major obesity centers in the country — at Yale, at University of Cincinnati, they’re all run by psychologists or psychiatrists. Here’s a physiological disorder of the body, and it’s being studied by psychologists and psychiatrists. They’re not interested in anecdotal evidence, unless it agrees with their preconceptions.

PRINCETON, New Jersey and UXBRIDGE, England, February 7 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the CASTLE study, in which 300 mg of once-daily REYATAZ(R) (atazanavir sulfate) taken with 100 mg of ritonavir (REYATAZ/r) showed similar antiviral efficacy to twice-daily lopinavir 400 mg and ritonavir 100 mg (lopinavir/r) in previously untreated adult HIV-1 infected patients at 48 weeks, as part of HIV combination therapy. In this study, 78 percent of the 440 patients in the REYATAZ/r arm met the primary endpoint of achieving undetectable viral load (defined as HIV-1 RNA less than 50 copies/mL) at 48 weeks, compared with 76 percent of the 443 patients in the lopinavir/r arm.